Clearance and Toxicity of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHu GDNF) Following Acute Convection-Enhanced Delivery into the Striatum

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Taylor, Hannah ^a   Barua, Neil ^a,b   Bienemann, Alison ^a   Wyatt, Marcella ^a   Castrique, Emma ^a   Foster, Rebecca ^a   Luz, Matthias ^c   Fibiger, Christian ^c   Mohr, Erich ^c   Gill, Steven ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c MedGenesis Therapeutix Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; LIATERMIN; MESSENGER RNA; NEUROMODULIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL ACTIVATION; CELL LOSS; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; CORPUS STRIATUM; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; RAT; SINGLE DRUG DOSE; SYNAPTOGENESIS;

ANIMALS; CELL DEATH; CORPUS STRIATUM; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INFUSION PUMPS; MALE; METABOLIC CLEARANCE RATE; NEUROGENESIS; NEUROGLIA; PARKINSON DISEASE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84875154887     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056186     Document Type: Article

References (31)

1. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F, (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
2. Clarkson ED, Zawada WM, Freed CR, (1995) GDNF reduces apoptosis in dopaminergic neurons in vitro. Neuroreport 7: 145-149.
3. Hou JG, Mytilineou C, (1996) Secretion of GDNF by glial cells does not account for the neurotrophic effect of bFGF on dopamine neurons in vitro. Brain Res 724: 145-148.
4. Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM, (1997) GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 17: 7111-7118.
5. Sullivan AM, Opacka-Juffry J, Blunt SB, (1998) Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10: 57-63.
6. Sauer H, Rosenblad C, Bjorklund A, (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci U S A 92: 8935-8939.
7. Maswood N, Grondin R, Zhang Z, Stanford JA, Surgener SP, et al. (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiol Aging 23: 881-889.
8. Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, et al. (2003) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23: 1974-1980.
9. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, et al. (2003) Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461: 250-261.
10. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, et al. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125: 2191-2201.
11. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
12. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, et al. (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11: 703-704.
13. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, et al. (2006) Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus 20: E1.
14. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466.
15. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, et al. (2007) Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27: 620-627.
16. Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, et al. (2006) GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 5: 200-202.
17. Hovland DN Jr, Boyd RB, Butt MT, Engelhardt JA, Moxness MS, et al. (2007) Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029.
18. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, et al. (2006) Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202: 497-505.
19. Jing S, Wen D, Yu Y, Holst PL, Luo Y, et al. (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85: 1113-1124.
20. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, et al. (1996) Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83.
21. Sarabi A, Hoffer BJ, Olson L, Morales M, (2001) GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 441: 106-117.
22. Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, et al. (2009) Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol 219: 499-506.
23. Barnett MW, Fisher CE, Perona-Wright G, Davies JA, (2002) Signalling by glial cell line-derived neurotrophic factor (GDNF) requires heparan sulphate glycosaminoglycan. J Cell Sci 115: 4495-4503.
24. Alfano I, Vora P, Mummery RS, Mulloy B, Rider CC, (2007) The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochem J 404: 131-140.
25. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, et al. (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91: 2076-2080.
26. Paxinos G, Watson C, Pennisi M, Topple A, (1985) Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods 13: 139-143.
27. Siew LK, Love S, Dawbarn D, Wilcock GK, Allen SJ, (2004) Measurement of pre- and post-synaptic proteins in cerebral cortex: effects of post-mortem delay. J Neurosci Methods 139: 153-159.
28. Morrison PF, Lonser RR, Oldfield EH, (2007) Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 107: 74-83.
29. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, et al. (2011) Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 54 Suppl 1: S196-203.
30. Gimenez F, Krauze MT, Valles F, Hadaczek P, Bringas J, et al. (2011) Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 54 Suppl 1: S189-195.
31. Bienemann A, White E, Woolley M, Castrique E, Johnson DE, et al. (2012) The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery. J Neurosci Methods 203: 284-291.